Rapid COVID-19 vaccine development

By Barney S. Graham. 2020

699 citations recorded by the source corpus.

Finding the fastest pathway to vaccine availability includes the avoidance of safety pitfalls Rapid development of a vaccine to prevent coronavirus disease 2019 (COVID-19) is a global imperative, and defining the stakes and potential hurdles is critical because regulatory and medical decisions are based on benefit:risk calculations. The ability of viruses to achieve pandemic spread is diminished by establishing higher levels of community (herd) immunity, and a key question is whether protection against severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) will happen by widespread deployment of an effective vaccine or by repeated waves of infection over the next few years until ∼60 to 70% of people develop immunity. Because the human population is naïve to SARS-CoV-2, the consequences of repeated epidemics will be unacceptably high mortality, severe economic disruption, and major adjustments to our way of life. Therefore, the benefit of developing an effective vaccine is very high, and even greater if it can be deployed in time to prevent repeated or continuous epidemics.

Subfields: Epidemiology, Health

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Ralph S. Baric
2. A. Walls
3. D. Veesler

Citations in the corpus

• Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, positive): “We compared the ratio of binding to neutralizing Abs elicited by S-2P and the RBD-8GS-, RBD-12GS-, and RBD16GS-I53-50 nanoparticles and HCS as a measure of the quality of the Ab responses elicited by the nanoparticle immunogens (Graham, 2020).”
• A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS (2020, neutral): “In general, the current CoV vaccine candidates can be classified into two categories: (1) gene-based vaccines including DNA/ messenger RNA vaccines, recombinant vaccine vectors, and live-virus vaccines, which produce antigens in host cells, and (2) protein-based vaccines including inactivated whole ”
• A Thermostable mRNA Vaccine against COVID-19 (2020, neutral): “An ideal COVID-19 vaccine is supposed to avoid induction of non-neutralizing antibody and Th2-biased cellular immune responses because of safety concerns (Graham, 2020).”
• An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020, neutral): “31 Reducing the risk of vaccine-associated enhanced respiratory disease or antibody-dependent enhancement of replication involves induction of high-quality functional antibody responses and Th1-biased T-cell responses.”